ResMed Inc. 10-Q Summary: Quarter Ended March 31, 2008
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2008, and the nine-month period ended on the same date. ResMed Inc. is a leading developer, manufacturer, and distributor of medical equipment for the diagnosis and treatment of sleep-disordered breathing (SDB) and other respiratory disorders. The company operates manufacturing facilities in Australia, France, and the United States, with major distribution sites globally.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2008 | Nine Months Ended Mar 31, 2008 |
|---|---|---|
| Net Revenues | $211.8 million | $600.2 million |
| Gross Profit | $126.6 million | $359.7 million |
| Gross Margin | 59.7% | 59.9% |
| Net Income | $29.7 million | $80.7 million |
| Diluted EPS | $0.38 | $1.02 |
| Cash and Cash Equivalents | $307.5 million (as of Mar 31, 2008) | |
| Total Debt | $132.2 million (Current: $16.2M; Long-term: $116.0M) | |
| Operating Cash Flow (9 months) | $81.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 16% for the quarter and 14% for the nine-month period compared to the prior year. Growth was driven by increased unit sales of flow generators, masks, and accessories, particularly new full-face masks. International sales grew 27% in the quarter, aided by favorable currency movements.
- Profitability Improvement: The quarter ended March 31, 2008, reported a net income of $29.7 million, a significant turnaround from a net loss of $15.4 million in the same period in 2007. The prior year's loss was heavily impacted by a $59.7 million voluntary product recall charge related to S8 flow generators, which did not recur in the current period.
- Margin Expansion: Gross margin improved to 59.7% in the current quarter compared to 29.6% in the prior year quarter (which included the recall charge). Excluding the recall, the prior year margin was 62.3%.
- One-Time Gains: The company recognized a $5.9 million gain on the sale and leaseback of its Poway, California property in the current quarter.
- Investment Impairment: A $3.25 million impairment charge was recorded for cost-method investments, offsetting some of the gains in "Other income."
Outlook, Risks, and Management Commentary
- Guidance Expectations: Management expects Selling, General, and Administrative (SG&A) expenses to remain in the range of 32% to 34% of net revenue. Research and Development (R&D) expenses are expected to continue in the range of 7% to 8% of net revenue.
- Liquidity and Capital Resources: The company maintains strong liquidity with $307.5 million in cash. Capital expenditures for the nine months were $57.6 million, primarily for the construction of a new corporate headquarters in San Diego and expansion of the Sydney manufacturing facility. The company has $45 million undrawn on its revolving credit facility.
- Product Recall Status: The voluntary recall of S8 flow generators initiated in April 2007 is ongoing. As of March 31, 2008, a remaining liability of $2.2 million is accrued. Management believes actual costs may differ from estimates.
- Legal Proceedings: The company is involved in routine litigation, including a German patent inventorship dispute (appeal granted in favor of ResMed) and an Australian university lawsuit regarding intellectual property. Management does not expect these to have a material adverse effect.
- Market Risks: Significant exposure exists to foreign currency fluctuations (AUD, EUR, GBP). The company utilizes foreign currency option contracts to hedge these risks. Interest rate risk is present on variable-rate debt, though a 10% change in rates is not expected to materially impact income.
Key Facts for Investor Verification
- Recall Liability Accuracy: Verify if the remaining $2.2 million accrual for the S8 product recall is sufficient given ongoing return rates and replacement costs.
- Investment Liquidity: Confirm the status of $5.0 million in auction rate securities reclassified to non-current assets due to failed auctions; assess potential liquidity constraints if immediate access to these funds is required.
- Construction Costs: Monitor the $76.7 million estimated remaining cost to complete the new San Diego headquarters and the company's ability to fund this via cash on hand and credit facilities.
- Foreign Exchange Impact: Evaluate the sustainability of revenue growth given the significant positive impact ($12.3 million in the quarter) from currency movements against the U.S. dollar.
- Debt Covenants: Confirm continued compliance with debt covenants, specifically the maximum debt-to-EBITDA ratio and minimum tangible net worth requirements under the revolving and syndicated facilities.